Minerva Deferred Long Term Liab vs Net Invested Capital Analysis

NERV Stock

USD 2.39 0.12 4.78%

Minerva Neurosciences financial indicator trend analysis is infinitely more than just investigating Minerva Neurosciences recent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Minerva Neurosciences is a good investment. Please check the relationship between Minerva Neurosciences Deferred Long Term Liab and its Net Invested Capital accounts. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Minerva Neurosciences. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in metropolitan statistical area.

For more information on how to buy Minerva Stock please use our How to Invest in Minerva Neurosciences guide.

Deferred Long Term Liab vs Net Invested Capital

Deferred Long Term Liab vs Net Invested Capital Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Minerva Neurosciences Deferred Long Term Liab account and Net Invested Capital. At this time, the significance of the direction appears to have strong relationship.

The correlation between Minerva Neurosciences' Deferred Long Term Liab and Net Invested Capital is 0.67. Overlapping area represents the amount of variation of Deferred Long Term Liab that can explain the historical movement of Net Invested Capital in the same time period over historical financial statements of Minerva Neurosciences, assuming nothing else is changed. The correlation between historical values of Minerva Neurosciences' Deferred Long Term Liab and Net Invested Capital is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Deferred Long Term Liab of Minerva Neurosciences are associated (or correlated) with its Net Invested Capital. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Net Invested Capital has no effect on the direction of Deferred Long Term Liab i.e., Minerva Neurosciences' Deferred Long Term Liab and Net Invested Capital go up and down completely randomly.

Correlation Coefficient

0.67

Relationship Direction	Positive
Relationship Strength	Significant

View All Relationships

Deferred Long Term Liab

Liabilities that are due after more than one year, including deferred tax liabilities and deferred revenue.

Net Invested Capital

The total amount of capital invested in a company, including both equity and debt, minus any cash or cash equivalents.

Most indicators from Minerva Neurosciences' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Minerva Neurosciences current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Minerva Neurosciences. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in metropolitan statistical area.

For more information on how to buy Minerva Stock please use our How to Invest in Minerva Neurosciences guide.At this time, Minerva Neurosciences' Selling General Administrative is fairly stable compared to the past year. Tax Provision is likely to climb to 0.00 in 2024, whereas Enterprise Value Over EBITDA is likely to drop (3.68) in 2024.

	2023	2024 (projected)
Extraordinary Items	8.5M	7.5M
Reconciled Depreciation	29.6K	57.8K

Extraordinary Items Reconciled Depreciation

Minerva Neurosciences fundamental ratios Correlations

	Total Assets	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Net Debt	Retained Earnings	Cash	Cash And Short Term Investments	Common Stock Total Equity	Common Stock Shares Outstanding	Other Current Assets	Other Stockholder Equity	Total Liab	Total Current Assets	Common Stock	Short Long Term Debt Total	Property Plant And Equipment Net	Current Deferred Revenue	Accounts Payable	Non Current Assets Total	Non Currrent Assets Other	Other Assets	Good Will	Non Current Liabilities Total	Property Plant And Equipment Gross	Short Term Debt
Total Assets		-0.47	0.81	0.76	-0.43	-0.34	0.65	0.96	0.65	0.46	-0.01	0.62	0.48	0.96	0.7	0.04	0.18	0.72	0.63	0.63	0.01	0.75	0.69	0.36	0.17	-0.36
Other Current Liab	-0.47		-0.48	-0.4	0.13	0.11	0.06	-0.5	-0.27	-0.24	-0.19	-0.28	-0.24	-0.5	-0.44	0.25	-0.7	-0.24	-0.45	-0.28	0.16	-0.28	-0.2	-0.18	-0.71	-0.1
Total Current Liabilities	0.81	-0.48		0.66	-0.45	-0.26	0.63	0.73	0.55	0.34	0.09	0.49	0.31	0.73	0.65	-0.05	0.37	0.67	0.65	0.59	0.04	0.71	0.65	0.16	0.39	-0.01
Total Stockholder Equity	0.76	-0.4	0.66		-0.72	0.26	0.31	0.67	0.2	-0.04	0.01	0.14	-0.1	0.66	0.7	-0.58	0.14	0.33	0.19	0.88	-0.5	0.88	0.24	-0.23	0.15	-0.33
Net Debt	-0.43	0.13	-0.45	-0.72		-0.22	-0.47	-0.41	-0.13	0.05	-0.35	-0.09	0.15	-0.41	-0.77	0.47	-0.23	-0.18	-0.24	-0.49	0.62	-0.56	-0.07	0.24	-0.13	0.32
Retained Earnings	-0.34	0.11	-0.26	0.26	-0.22		-0.57	-0.41	-0.87	-0.91	-0.4	-0.91	-0.82	-0.42	-0.28	-0.78	-0.3	-0.73	-0.7	0.41	-0.55	0.14	-0.79	-0.8	-0.27	0.05
Cash	0.65	0.06	0.63	0.31	-0.47	-0.57		0.68	0.73	0.63	0.15	0.7	0.59	0.69	0.54	0.42	0.01	0.7	0.64	0.1	0.16	0.33	0.69	0.51	-0.05	-0.26
Cash And Short Term Investments	0.96	-0.5	0.73	0.67	-0.41	-0.41	0.68		0.68	0.58	0.01	0.66	0.57	1.0	0.67	0.13	0.15	0.66	0.67	0.47	0.05	0.59	0.64	0.48	0.13	-0.35
Common Stock Total Equity	0.65	-0.27	0.55	0.2	-0.13	-0.87	0.73	0.68		0.92	0.42	0.99	0.81	0.69	0.61	0.5	0.37	0.91	0.79	-0.05	0.26	0.27	0.91	0.74	0.33	-0.18
Common Stock Shares Outstanding	0.46	-0.24	0.34	-0.04	0.05	-0.91	0.63	0.58	0.92		0.4	0.94	0.83	0.59	0.42	0.6	0.29	0.7	0.76	-0.31	0.41	-0.05	0.73	0.8	0.26	-0.17
Other Current Assets	-0.01	-0.19	0.09	0.01	-0.35	-0.4	0.15	0.01	0.42	0.4		0.45	0.04	0.02	0.63	-0.01	0.65	0.29	0.33	-0.27	-0.2	-0.09	0.25	0.0	0.55	0.13
Other Stockholder Equity	0.62	-0.28	0.49	0.14	-0.09	-0.91	0.7	0.66	0.99	0.94	0.45		0.82	0.67	0.59	0.54	0.39	0.88	0.79	-0.1	0.29	0.2	0.89	0.75	0.35	-0.19
Total Liab	0.48	-0.24	0.31	-0.1	0.15	-0.82	0.59	0.57	0.81	0.83	0.04	0.82		0.58	0.23	0.73	0.16	0.71	0.74	-0.27	0.4	0.0	0.73	0.99	0.11	-0.14
Total Current Assets	0.96	-0.5	0.73	0.66	-0.41	-0.42	0.69	1.0	0.69	0.59	0.02	0.67	0.58		0.67	0.15	0.15	0.67	0.67	0.47	0.05	0.58	0.65	0.49	0.13	-0.35
Common Stock	0.7	-0.44	0.65	0.7	-0.77	-0.28	0.54	0.67	0.61	0.42	0.63	0.59	0.23	0.67		-0.22	0.57	0.63	0.63	0.43	-0.36	0.62	0.54	0.12	0.48	-0.29
Short Long Term Debt Total	0.04	0.25	-0.05	-0.58	0.47	-0.78	0.42	0.13	0.5	0.6	-0.01	0.54	0.73	0.15	-0.22		-0.21	0.4	0.35	-0.59	0.7	-0.43	0.5	0.78	-0.25	0.18
Property Plant And Equipment Net	0.18	-0.7	0.37	0.14	-0.23	-0.3	0.01	0.15	0.37	0.29	0.65	0.39	0.16	0.15	0.57	-0.21		0.35	0.56	0.03	-0.19	0.16	0.3	0.1	0.98	0.04
Current Deferred Revenue	0.72	-0.24	0.67	0.33	-0.18	-0.73	0.7	0.66	0.91	0.7	0.29	0.88	0.71	0.67	0.63	0.4	0.35		0.74	0.23	0.2	0.54	0.99	0.6	0.33	-0.16
Accounts Payable	0.63	-0.45	0.65	0.19	-0.24	-0.7	0.64	0.67	0.79	0.76	0.33	0.79	0.74	0.67	0.63	0.35	0.56	0.74		0.05	0.29	0.27	0.75	0.67	0.51	-0.27
Non Current Assets Total	0.63	-0.28	0.59	0.88	-0.49	0.41	0.1	0.47	-0.05	-0.31	-0.27	-0.1	-0.27	0.47	0.43	-0.59	0.03	0.23	0.05		-0.34	0.93	0.17	-0.38	0.08	-0.33
Non Currrent Assets Other	0.01	0.16	0.04	-0.5	0.62	-0.55	0.16	0.05	0.26	0.41	-0.2	0.29	0.4	0.05	-0.36	0.7	-0.19	0.2	0.29	-0.34		-0.34	0.36	0.44	-0.13	0.11
Other Assets	0.75	-0.28	0.71	0.88	-0.56	0.14	0.33	0.59	0.27	-0.05	-0.09	0.2	0.0	0.58	0.62	-0.43	0.16	0.54	0.27	0.93	-0.34		0.46	-0.13	0.19	-0.36
Good Will	0.69	-0.2	0.65	0.24	-0.07	-0.79	0.69	0.64	0.91	0.73	0.25	0.89	0.73	0.65	0.54	0.5	0.3	0.99	0.75	0.17	0.36	0.46		0.64	0.29	-0.14
Non Current Liabilities Total	0.36	-0.18	0.16	-0.23	0.24	-0.8	0.51	0.48	0.74	0.8	0.0	0.75	0.99	0.49	0.12	0.78	0.1	0.6	0.67	-0.38	0.44	-0.13	0.64		0.05	-0.14
Property Plant And Equipment Gross	0.17	-0.71	0.39	0.15	-0.13	-0.27	-0.05	0.13	0.33	0.26	0.55	0.35	0.11	0.13	0.48	-0.25	0.98	0.33	0.51	0.08	-0.13	0.19	0.29	0.05		0.03
Short Term Debt	-0.36	-0.1	-0.01	-0.33	0.32	0.05	-0.26	-0.35	-0.18	-0.17	0.13	-0.19	-0.14	-0.35	-0.29	0.18	0.04	-0.16	-0.27	-0.33	0.11	-0.36	-0.14	-0.14	0.03

Click cells to compare fundamentals

Minerva Neurosciences Account Relationship Matchups

Minerva Neurosciences fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	77.5M	57.6M	77.1M	55.1M	56.9M	88.0M
Other Current Liab	(41.2B)	2.1M	965.7K	407.9K	1.5M	1.6M
Total Current Liabilities	6.6M	3.2M	2.8M	1.4M	3.3M	4.4M
Total Stockholder Equity	27.8M	52.7M	8.0M	(20.0M)	(28.5M)	(27.0M)
Net Debt	(21.1M)	(25.2M)	(60.8M)	37.6M	41.0M	43.1M
Retained Earnings	(286.7M)	(284.8M)	(334.7M)	(366.8M)	(396.8M)	(377.0M)
Cash	21.4M	25.4M	60.8M	36.1M	41.0M	34.7M
Cash And Short Term Investments	45.9M	25.4M	60.8M	36.1M	41.0M	51.4M
Common Stock Total Equity	3.9K	3.9K	3.9K	4.3K	4.9K	3.0K
Common Stock Shares Outstanding	4.9M	5.1M	5.3M	5.3M	6.5M	4.6M
Liabilities And Stockholders Equity	77.5M	57.6M	77.1M	55.1M	56.9M	88.0M
Other Current Assets	1.3B	2.1B	1.4B	4.0M	989.9K	940.4K
Other Stockholder Equity	314.5M	337.5M	342.7M	346.8M	368.4M	264.5M
Total Liab	49.7M	5.0M	69.1M	75.1M	85.4M	42.7M
Total Current Assets	47.1M	27.4M	62.2M	40.2M	42.0M	52.9M
Common Stock	3.9K	4K	4.3K	534.0	699.0	664.05
Property Plant And Equipment Net	278K	101.8K	51.1K	16.3K	10.9K	10.3K
Accounts Payable	2.3M	995.6K	1.9M	969.7K	1.8M	1.5M
Non Current Assets Total	30.4M	30.2M	14.9M	14.9M	14.9M	27.9M
Non Current Liabilities Total	43.1M	1.8M	66.3M	73.7M	82.0M	41.8M
Property Plant And Equipment Gross	278.0K	101.8K	0.0	16.3K	18.8K	17.8K
Short Term Debt	4.0M	(41.2B)	173K	111.2K	100.1K	105.1K
Property Plant Equipment	33.5K	16.0K	101.8K	16.3K	18.8K	36.8K
Other Liab	43.0M	1.8M	66.3M	73.7M	84.8M	89.0M
Net Tangible Assets	(2.3M)	22.6M	(6.9M)	(34.9M)	(31.4M)	(29.9M)
Retained Earnings Total Equity	(164.4M)	(214.6M)	(286.7M)	(284.8M)	(256.3M)	(269.1M)
Capital Surpluse	296.0M	304.8M	314.5M	337.5M	388.1M	278.9M
Non Current Liabilities Other	41.2M	41.3M	66.3M	73.7M	82.0M	41.9M
Net Invested Capital	27.8M	52.7M	8.0M	(20.0M)	(28.5M)	(27.0M)
Net Working Capital	40.5M	24.3M	59.4M	38.8M	38.7M	46.9M

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect

When determining whether Minerva Neurosciences is a strong investment it is important to analyze Minerva Neurosciences' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Minerva Neurosciences' future performance. For an informed investment choice regarding Minerva Stock, refer to the following important reports:

How To Invest In Minerva

Details

Is Minerva Stock a good investment?

Details

What is Minerva Neurosciences' Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Minerva Neurosciences. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in metropolitan statistical area.

For more information on how to buy Minerva Stock please use our How to Invest in Minerva Neurosciences guide.

You can also try the Price Transformation module to use Price Transformation models to analyze the depth of different equity instruments across global markets.

Complementary Tools for Minerva Stock analysis

When running Minerva Neurosciences' price analysis, check to measure Minerva Neurosciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Minerva Neurosciences is operating at the current time. Most of Minerva Neurosciences' value examination focuses on studying past and present price action to predict the probability of Minerva Neurosciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Minerva Neurosciences' price. Additionally, you may evaluate how the addition of Minerva Neurosciences to your portfolios can decrease your overall portfolio volatility.

	Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets
	ETFs Find actively traded Exchange Traded Funds (ETF) from around the world
	USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA
	Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings
	Portfolio Anywhere Track or share privately all of your investments from the convenience of any device

Is Minerva Neurosciences' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Minerva Neurosciences. If investors know Minerva will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Minerva Neurosciences listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(4.43)

Return On Assets

(0.30)

Return On Equity

(6.75)

The market value of Minerva Neurosciences is measured differently than its book value, which is the value of Minerva that is recorded on the company's balance sheet. Investors also form their own opinion of Minerva Neurosciences' value that differs from its market value or its book value, called intrinsic value, which is Minerva Neurosciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Minerva Neurosciences' market value can be influenced by many factors that don't directly affect Minerva Neurosciences' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Minerva Neurosciences' value and its price as these two are different measures arrived at by different means. Investors typically determine if Minerva Neurosciences is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Minerva Neurosciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Minerva Deferred Long Term Liab vs Net Invested Capital Analysis

Deferred Long Term Liab vs Net Invested Capital

Deferred Long Term Liab vs Net Invested Capital Correlation Analysis

Correlation Coefficient

Deferred Long Term Liab

Net Invested Capital

Minerva Neurosciences fundamental ratios Correlations

Minerva Neurosciences Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Minerva Neurosciences fundamental ratios Accounts

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

Complementary Tools for Minerva Stock analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Total Current Assets	+ 1.0	Cash And Short Term Investments
Other Stockholder Equity	+ 0.99	Common Stock Total Equity
Non Current Liabilities Total	+ 0.99	Total Liab
Good Will	+ 0.99	Current Deferred Revenue
Property Plant And Equipment Gross	+ 0.98	Property Plant And Equipment Net
Cash And Short Term Investments	+ 0.96	Total Assets

Other Stockholder Equity	- 0.91	Retained Earnings
Common Stock Shares Outstanding	- 0.91	Retained Earnings
Common Stock Total Equity	- 0.87	Retained Earnings
Total Liab	- 0.82	Retained Earnings
Non Current Liabilities Total	- 0.8	Retained Earnings
Good Will	- 0.79	Retained Earnings